ALK Variant 1 Confers Better Efficacy With Crizotinib in NSCLC

Share this content:
Crizotinib may be clinically beneficial for patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) variant 1.
Crizotinib may be clinically beneficial for patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) variant 1.

Crizotinib may be clinically beneficial for patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) variant 1, as opposed to other variants, according to a study published in the Journal of Clinical Oncology.1

ALK rearrangement-positive NSCLC can be treated with an ALK tyrosine kinase inhibitor, such as crizotinib, ceritinib, and alectinib, though the response magnitude and duration are mixed. Because several variants in ALK have been identified, researchers evaluated the impact of different ALK variants on the efficacy of crizotinib in patients with ALK mutation-positive NSCLC.

Investigators analyzed data from 35 patients treated with crizotinib as the initial ALK kinase inhibitor between 2007 and 2014. ALK variants were assessed via reverse transcription polymerase chain reaction; efficacy of crizotinib was retrospectively evaluated on the basis of objective response rate and progression-free survival with respect to ALK variants.

Researchers found that the most common ALK variant was variant 1, which was found in 54% of patients, followed by variant 2 in 14%, variant 3a/3b in 12%, and other variants observed in 20%.

Results showed that objective response rate was 69% among all patients, but was 74% in the variant 1 group versus 63% in non-variant 1 groups. Median progression-free survival was 11.0 months (95% CI, 6.5-43.0), compared with 4.2 months (95% CI, 1.5-10.2), respectively (P < .05).

RELATED: First-line Nivolumab Monotherapy Induces Durable Responses in Advanced NSCLC

The study demonstrated that ALK variant 1 (hazard ratio, 0.350; 95% CI, 0.128-0.929) and advanced stage of cancer (hazard ratio, 4.646; 95% CI, 1.381-21.750) were significantly associated with median progression-free survival (P < .05).                             

Reference

  1. Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer [published online ahead of print June 27, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.65.8732.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters